Knight Therapeutics Q2: 58% EBITDA Growth Looks Clean-Until You Ask Who's Really Buying

Knight's operating numbers improved, but ownership alignment is the harder question

Knight's Q2 results are strong on the face of it. Adjusted EBITDA rose 58%, the company delivered a record first-half performance, and it raised 2026 revenue guidance. That is enough to justify a firmer look from investors who want to see a rerating.

But the more important question is whether that optimism is being backed by real capital. A stronger income statement matters, but it matters more if insiders, management, and outside holders are also putting money behind the story.

What the ownership signal currently shows

Knight has already taken one meaningful step in that direction: it bought back 1.5 million common shares in the first half for about CAD 9.2 million. Buybacks are a simple alignment signal because they commit capital rather than just talk about it.

By contrast, management's governance messaging remains generic. Knight says it follows sound principles of corporate governance and points to a seasoned management team. That is standard and not unhelpful, but it is not the same thing as proof of conviction.

Why the next ownership data point matters

The operating story now looks credible enough that the market can argue for a higher bar. The next test is whether the ownership base starts to confirm that view through repeat buybacks, insider buying, and external holders adding size through filings. Without that, the rally can still be driven mostly by expectations rather than concentrated, long-term capital.

Knight's Q2 improved in the right ways, but execution risks now matter more

Knight's quarter was not only bigger; some of the highest-quality lines improved the most. First-half revenue reached CAD 293 million, the promoted portfolio delivered nearly CAD 200 million, and launch pipeline generated CAD 18 million in second-quarter revenue, up 297% year over year on a constant-currency basis. That mix suggests the growth was coming from products that are actually moving, not from one-off noise.

What the quarter proves

The clearest improvement was operating leverage, not just revenue growth. Adjusted gross margin in Q2 2026 was 49% of revenues, up from 46%, helping lift adjusted EBITDA rose 58% to more than CAD 24 million. Within the promoted mix, promoted strategic products revenue was CAD 76 million, and excluding AmbiStorm sales to MOH, the portfolio grew by 16% on a constant currency basis.

That is what disciplined buyers want to see: commercial traction paired with better margin performance. After the raised 2026 revenue outlook, the market no longer needs proof that Knight is growing. It now needs proof that the business is also becoming more efficient as it scales.

Which frictions now deserve the most attention

The next leg of the story has more resistance than the first. Health Canada issued a Notice of Non-Compliance for CREXONT, which creates timing risk around that Canadian launch path. There are also other pressure points:

• LENVIMA is expected to face a material price reduction in Colombia
• AmBisome sales to Brazil's Ministry of Health are not expected to recur in the second half
• Operating expenses in Q2 2026 increased 25%

These are not, on their own, company-breaking issues. But they matter more now because guidance has been lifted. When expectations rise, investors start underwriting a higher base case, which makes each operational or pricing friction more important.

The next confirmation signals are simpler than the narrative

The core question is no longer whether Knight can execute commercially. It is whether the ownership base is starting to back that execution with more capital.

What would count as confirmation

The cleanest signal is more capital at work. Knight started that process with its first-half repurchases, and a repeat or expansion of that behavior would matter. So would:

• insider buying, rather than only broad governance language about sound principles of corporate governance
• continued operating cash generation against Cash and Marketable Securities already at a solid level
• external holders adding size through filings, which would suggest outside investors are following management's story with their own money

What would weaken the setup

The bear case is already grounded in visible items from the quarter and call. The same Notice of Non-Compliance for CREXONT, the Colombia pricing pressure on LENVIMA, the nonrecurring AmBisome sales, and Operating expenses in Q2 2026 increased 25% are the practical watchpoints.

If those frictions worsen and ownership commitment does not deepen, the market can stop rewarding the growth narrative and start focusing more on EBITDA quality. If buybacks continue and the regulatory and pricing issues prove temporary, the rally is more likely to keep credibility.